No CrossRef data available.
Published online by Cambridge University Press: 16 April 2020
It is well known that incidence of hepatitis C is much higher in risk population known as drug abusers. Interferon implementation in hepatitis C therapy contributed better prognosis for this patients. However during the interferon treatment the risk of psychiatric adverse events increases. Between 20-40% of those patients developed psychiatric adverse events which are one of the main reasons of therapy abruption. Only intensive psychiatric evaluation and adequate psychopharmacological treatment provide continuation of the interferon therapy. In this paper we observed frequency of interferon therapy and psychopharmacotherapy during the determinate period of on year in drug abusers in our Hospital.
Comments
No Comments have been published for this article.